علاج سرطان الدم البروليمفاوي من الخلايا البائية مع حذف أو طفرة TP53

References

1. For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.
2. For those patients with nonfunctional TP53, alemtuzumab has historically been the mainstay of treatment and, although no longer licensed in CLL, is available via a patient access scheme.
3. For this reason, suitable patients may be considered for early allogenic SCT, as in T-PLL.
4. For these reasons, it is appropriate to consider potentially curative treatment with allogenic SCT in first remission for eligible patients.